

Special Issue

Imaging Biomarkers in Oncology

Message from the Guest Editors

In the last decade, oncology has seen dramatic advancements that have revolutionized cancer care, allowing for a more personalized treatment approach and overall improved patient management in an increasing proportion of clinical scenarios. In this context, medical imaging plays a key role in defining and evaluating specific imaging biomarkers, intended as objective imaging-based indicators that may serve to refine or enhance diagnostic information obtained by conventional image analysis, assess early therapeutic responses, predict individual outcomes, and guide treatment based on patient- and disease-specific features. The purpose of this Special Issue is to collect evidence from the latest research landscape regarding the status of imaging biomarkers in oncology, with a special focus on radiomics and its evolving role in the advanced management of the most common and paradigmatic cancers.

Guest Editors

Dr. Lorenzo Faggioni

Department of Translational Research, University of Pisa, 56126 Pisa, Italy

Dr. Dania Cioni


Department of Surgery, University of Pisa, 56126 Pisa, Italy

Dr. Michela Gabelloni

Department of Translational Research, University of Pisa, 56126 Pisa, Italy

Deadline for manuscript submissions

closed (30 June 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/123265

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).